Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with LECIG by analysis of interim data from the ELEGANCE study (NCT05043103).
Background: The availability of LECIG infusion since 2018 has expanded the options for device-aided therapy for people with advanced PD. As the formulation incorporates entacapone within the infusion, a lower levodopa dose in a smaller volume to be given while still maintaining therapeutically effective plasma levels.1 This has practical advantages as the medication can be delivered via small, lightweight pump. ELEGANCE is a large, ongoing non-interventional study (NCT05043103) collecting safety, efficacy and patient-reported outcomes data from patients treated with LECIG in routine clinical practice in 13 European countries.
Method: Study participants are advanced PD patients with severe motor fluctuations and hyperkinesia or dyskinesia despite optimised PD therapy who have been prescribed LECIG as part of routine clinical care. This interim analysis evaluated data for 167 patients. Clinical Global Impression of Improvement was rated separately by clinicians (CGI-I) and patients (PCI-I) from visit 2 (3–6 months of treatment) onwards on a seven-point scale: ‘Compared to the patient’s condition at baseline (prior to medication initiation), their condition is: 1=very much improved to 7=very much worse’. A mean score of 4.0 indicates no change.
Results: Both CGI-I (Figure 1) and PGI-I (Figure 2) were significantly improved compared with baseline up to visit 4 (12–18 months of treatment). Improvements were also seen at visit 5 but did not reach statistical significance due to low patient numbers.
Conclusion: Both clinicians and PD patients report sustained favourable improvements in their disease following treatment with LECIG for up to two years compared with their baseline condition.
Figure 1
Figure 2
References: 1. Senek M, et al. Mov Disord. 2017;32(2):283-6.
To cite this abstract in AMA style:
N. Smith, B. Amlani. Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/patient-and-clinician-perceptions-of-disease-improvement-with-levodopa-entacapone-carbidopa-intestinal-gel-lecig-in-advanced-parkinsons-data-from-the-elegance-inte/. Accessed November 20, 2025.« Back to 2025 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/patient-and-clinician-perceptions-of-disease-improvement-with-levodopa-entacapone-carbidopa-intestinal-gel-lecig-in-advanced-parkinsons-data-from-the-elegance-inte/